| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Precigen Inc (NASDAQ: PGEN)
PGEN Technical Analysis
5
| As on 9th Jun 2023 PGEN STOCK Price closed @ 1.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.05 & Strong Sell for SHORT-TERM with Stoploss of 2.77 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PGENSTOCK Price
| Open | 1.26 | Change | Price | % |
| High | 1.29 | 1 Day | -0.08 | -6.35 |
| Low | 1.18 | 1 Week | -0.01 | -0.84 |
| Close | 1.18 | 1 Month | 0.01 | 0.85 |
| Volume | 1086600 | 1 Year | -2.79 | -70.28 |
| 52 Week High 4.10 | 52 Week Low 0.88 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| PGEN Daily Charts |
PGEN Intraday Charts |
Whats New @ Bazaartrend |
PGEN Free Analysis |
|
|
PGEN Important Levels Intraday
| RESISTANCE | 1.39 |
| RESISTANCE | 1.32 |
| RESISTANCE | 1.28 |
| RESISTANCE | 1.24 |
| SUPPORT | 1.12 |
| SUPPORT | 1.08 |
| SUPPORT | 1.04 |
| SUPPORT | 0.97 |
PGEN Forecast May 2024
| 4th UP Forecast | 3.72 |
| 3rd UP Forecast | 2.91 |
| 2nd UP Forecast | 2.4 |
| 1st UP Forecast | 1.9 |
| 1st DOWN Forecast | 0.46 |
| 2nd DOWN Forecast | -0.04 |
| 3rd DOWN Forecast | -0.55 |
| 4th DOWN Forecast | -1.36 |
PGEN Weekly Forecast
| 4th UP Forecast | 2.07 |
| 3rd UP Forecast | 1.78 |
| 2nd UP Forecast | 1.61 |
| 1st UP Forecast | 1.43 |
| 1st DOWN Forecast | 0.93 |
| 2nd DOWN Forecast | 0.75 |
| 3rd DOWN Forecast | 0.58 |
| 4th DOWN Forecast | 0.29 |
PGEN Forecast2024
| 4th UP Forecast | 7.65 |
| 3rd UP Forecast | 5.58 |
| 2nd UP Forecast | 4.29 |
| 1st UP Forecast | 3.01 |
| 1st DOWN Forecast | -0.65 |
| 2nd DOWN Forecast | -1.93 |
| 3rd DOWN Forecast | -3.22 |
| 4th DOWN Forecast | -5.29 |
Precigen Inc ( NASDAQ USA Symbol : PGEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PGEN Business Profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland. Address: 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service